2024 | Contineum Therapeutics

Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis

May 9, 2024/in Publications, 2024/by David Anderson

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana O. Lorenzana, Bryanna E. Paulson, Christopher S. Baccei, Jeffrey R. Roppe, Thomas O. Schrader, Lino J. Valdez, Yifeng Xiong, Austin C. Chen & Daniel S. Lorrain

Scientific Reports

Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis

July 31, 2024/in Publications, 2024/by David Anderson

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana J. Lorenzana, Jeffrey R. Roppe, Jill M. Baccei, Christopher S. Baccei, Austin C. Chen, Ari J. Green, Daniel S. Lorrain, and Jonah R. Chan

PNAS

Lysophosphatidic Acid Receptor Subtype-1 Antagonist PIPE-791 Reduces Neuropathic Pain in Macaques

August 12, 2024/in Publications, 2024/by David Anderson

Aldric Hama, Karin Stebbins, Chris Baccei, Daniel Lorrain, Austin Chen, Takahiro Natsume, Hiroryuki Takamatsu

Presented at IASP 2024 World Congress on Pain

Active MS lesions are characterized by high LPA1 expression and PIPE-791 promotes remyelination via LPA1 inhibition in the cuprizone model

March 17, 2024/in Publications, 2024/by David Anderson

Didier Bagnol, Alexander R Broadhead, Geraldine C Edu, John Atkins, Christopher S Baccei, Kym I Lorrain, Michael M Poon, Jeffrey R Roppe, Thomas O Schrader, Lino J Valdez, Yifeng Xiong, Austin C Chen, Daniel S Lorrain

Presented at Gordon Research Conference (GRC) 2024